Nitric oxide is under clinical development by NOxy Health Products and currently in Phase I for Diabetic Foot Ulcers. According to GlobalData, Phase I drugs for Diabetic Foot Ulcers does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Nitric oxide LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Nitric oxide overview
Nitric oxide (NOX-1416) is under development for the treatment of diabetic foot ulcers. The drug candidate is administered through topical route in the form of foam. It acts by targeting guanylate cyclase.
NOxy Health Products overview
NOxy Health Products is a healthcare company that focuses on developing innovative medicines to heal chronic wounds with the help of nitric oxide. The company is headquartered in San Mateo, California, the US.
For a complete picture of Nitric oxide’s drug-specific PTSR and LoA scores, buy the report here.